Table 2 Clinicopathologic features of training group stratified by methylation clusters

Total, n

233

67(28.8%)

53(22.7%)

90(38.6%)

23(9.9%)

Mean age, y

60.1 ± 11.21

62.34 ± 11.84

57.03 ± 10.12

61.96 ± 10.45

Stage

0.471

 I

7(3.0%)

2(3.0%)

2(3.8%)

3(3.3%)

0

 II

8(3.4%)

1(1.5%)

2(3.8%)

4(4.4%)

1(4.3%)

 III

185(79.4%)

53(79.1%)

47(88.7%)

66(73.3%)

19(82.6%)

 IV

33(14.2%)

11(16.4%)

2(3.8%)

17(18.9%)

3(13.0%)

Primary therapy outcome

0.227

 Complete remission

140(60.1%)

36(53.7%)

32(60.4%)

62(68.9%)

10(43.5%)

 Partial remission

25(10.7%)

6(9.0%)

4(7.5%)

10(11.1%)

5(21.7%)

 Progressive disease

14(6.0%)

7(10.4%)

2(3.8%)

3(3.3%)

2(8.7%)

 Stable disease

15(6.4%)

4(6.0%)

5(9.4%)

3(3.3%)

3(13.0%)

 Unknown

39(16.7%)

14(20.9%)

10(18.9%)

12(13.3%)

3(13.0%)

Tumour residual

0.027

 No macroscopic disease

50(21.5%)

12(17.9%)

19(35.8%)

17(18.9%)

2(8.7%)

 1–10 mm

100(42.9%)

36(53.7%)

13(24.5%)

40(44.4%)

11(47.8%)

 11–20 mm

15(6.4%)

3(4.5%)

7(13.2%)

3(3.3%)

2(8.7%)

 > 20 mm

48(20.6%)

10(14.9%)

9(17.0%)

22(24.4%)

7(30.4%)

 Unknown

20(8.6%)

6(9.0%)

5(9.4%)

8(8.9%)

1(4.3%)

Venous invasion

0.270

 No

29(12.4%)

8(11.9%)

12(22.6%)

8(8.9%)

1(4.3%)

 Yes

41(17.6%)

12(17.9%)

8(15.1%)

17(18.9%)

4(17.4%)

 Unknown

163(70.0%)

47(70.1%)

33(62.3%)

65(72.2%)

18(78.3%)

Lymphatic invasion

0.031

 No

33(14.2%)

8(11.9%)

13(24.5%)

10(11.1%)

2(8.7%)

 Yes

60(25.8%)

23(34.3%)

5(9.4%)

25(27.8%)

7(30.4%)

 Unknown

140(60.1%)

36(53.7%)

35(66.0%)

55(61.1%)

14(60.9%)

Survival status

0.0001

 5y OS

34.8%

17.7%

57.4%

40.1%

6.8%

 10y OS

16.3%

7.9%

21.7%

22.3%

6.8%

 Median OS (months)

46

35

64

48

24

 Median 95%CI (months)

38.3–53.7

32.2–37.8

48.3–81.7

40.1–59.9

17.2–32.7